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Abstract: Primary central nervous system lymphoma (PCNSL) constitutes a rare group of extranodal non-Hodgkin’s lymphoma (NHL) 
primarily of B cell origin. It occurs in both immuno-competent and immune-compromised patients. High dose m  ethotrexate (HD-MTX) 
based chemotherapy is the standard therapy. Chemotherapy with whole brain radiation therapy (WBRT) improves response rates and 
survival compared with WBRT alone. However, due to the increased risk for neurotoxicity with WBRT, recent st  udies have focused on 
using chemotherapy alone. Methotrexate based multi-agent chemotherapy without WBRT is associated with similar t  reatment rates and 
survival compared with regimens that include WBRT although controlled trials have not been performed. Because of the low in  cidence 
of this disease, it is difficult to conduct randomized controlled trials. In this article we have discussed about the past, present and emerg-
ing treatment options in patients with PCNSL.
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Primary central nervous system lymphoma (PCNSL)   
is  an  aggressive,  rare  extra-nodal  non-Hodgkin’s 
lymphoma  (NHL)  that  involves  the  brain,  spinal 
cord, meninges and eyes. It occurs in both immu-
nocompetent  and  immunocompromised  patients. 
Median  age  at  diagnosis  is  between  60–65  years. 
It  represents  about  4%  of  all  primary  intracranial 
neoplasms.   Contrast-enhanced cranial magnetic reso-
nance   imaging (MRI) is the best imaging modality 
for assessment. Surgical resection should be limited 
to patients with impending herniation and ventricular 
dilatation. The most common presenting symptoms 
include focal neurologic deficits, signs and   symptoms 
of increased intracranial pressure, personality changes, 
seizures and ocular symptoms.
PCNSL  is  classified  as  stage  IE  by Ann Arbor 
  classification.  The  important  components  of  stag-
ing  are  to  exclude  concomitant  systemic  disease 
and  ocular  involvement.  Testicular  ultrasound  is 
recommended in elderly patients to exclude testicu-
lar    lymphoma.  Cerebrospinal  fluid  analysis  (CSF) 
should be done in all patients and should be sent for 
cell count,   protein, glucose, cytology, flow cytometry 
and PCR. HIV   testing is suggested in all patients. 
Bone marrow   aspirate and biopsy is recommended in 
all patients. Currently there is no role for (fluorode-
oxyglucose-positron emission  tomography) scan  in 
patients with PCNSL.
Most of the clinical trials use the International 
Extranodal Lymphoma Study Group (IELSG) prog-
nostic scoring system which uses age, performance 
status, serum lactate dehydrogenase level, cerebro-
spinal fluid protein concentration, and the involve-
ment  of  deep  structures  as  the  risk  stratifying 
factors.1 The prognostic scoring system developed 
by  the  Memorial  Sloan  Kettering  Cancer  Center 
uses age and performance status as risk stratify-
ing factors and it has been validated in the RTOG 
PCNSL  clinical  trials.2  To  ensure  similarity  and 
increase the communication among the investiga-
tors conducting the clinical trials for newly diag-
nosed patients with PCNSL, an international group 
of experts representing hematologic oncology, med-
ical oncology, neuro-oncology, neurology, radiation 
oncology, neurosurgery, and ophthalmology met to 
review current standards and devised a consensus 
opinion  regarding  minimum  baseline  evaluation 
and response assessment.3
pathogenesis
The  most  common  histopathologic  subtype  is 
  diffuse  large  B-cell  lymphoma  (DLBCL)  seen  in 
about  90%  of  patients.  Rarely,  PCNSL  may  pres-
ent  like  Burkitt  l  ymphoma,  marginal  zone  lym-
phoma, lymphoblastic lymphoma, small lymphocytic 
  lymphoma or Hodgkin Lymphoma. T cell lymphomas 
compose about 2% of PCNSL in western countries 
and  about  8%  in  Japan. The  exact  pathogenesis  of 
PCNSL is still unclear in immunocompetent patients. 
Epstein-Barr virus plays a role in the pathogenesis in 
immunocompromised patients. However, recent evi-
dence suggests that Primary CNS DLBCL is derived 
from peripheral B cells activated by antigenic stimula-
tion and enter the brain through connections between 
various extracellular matrix and adhesion molecules.4 
T  hompsett et al have also demonstrated a high fre-
quency of somatic hypermutation pattern suggesting 
the role of antigenic stimulation.5 Sasayama et al mea-
sured the cerebrospinal fluid (CSF) levels of IL-10 and 
IL-6 in 66 patients with intracranial tumors and found 
the median CSF levels of IL-10 and IL-6 were 27 pg/mL 
and 5.4 pg/mL, respectively in patients with PCNSL. 
The levels were significantly higher in PCNSLs than in 
the other brain tumors. The sensitivity and specificity 
of 71.0% and 100% respectively was found with an 
IL-10 cut off level of 9.5 pg/mL. The CSF IL-10 level 
might be a useful diagnostic and prognostic biomarker 
in patients with PCNSLs.6 Del (6) (q22) was found to 
be associated with decreased overall survival and is 
present in about 50% of patients.7 Rubenstein et al has 
shown that high expression of STAT6 was associated 
with a shorter survival in patients treated with high- 
dose intravenous methotrexate and have also identified 
several IL-4 induced genes in patients with PCNSL.8
BCL-6 is frequently expressed in PCNSL, but the 
data is conflicting on its prognostic value. Braaten et al 
have shown that BCL-6 expression was associated 
with favorable prognosis,9 while Chang et al showed 
a trend towards poor prognosis.10   Similarly, Song et al 
has shown that Bcl-6 expression was associated with 
higher PFS and OS in patients having non-deep-site 
involvement in the brain.11 It had no prognostic value 
in patients who had deep-site involvement.
Camilleri-Broet et al evaluated 83 cases of PCNSL 
and found that the majority had a phenotype indica-
tive of the activated B-cell type.12 This is in contrast 
to    earlier  studies  that  suggested  a  germinal  center Treatment of primary central nervous system lymphoma
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B-cell type derivation.13,14 In their study they have aslo 
reported that BCL-6 expression had no effect on the 
outcome of patients with PCNSL. Baraniskin et al have 
demonstrated that CSF micro RNA’s could be a useful 
tool for the diagnosis of PCNSL.15 Among the micro 
RNA’s miR-21, miR-19 and miR-92a were found to be 
diagnostic. Kim et al failed to demonstrate the prognos-
tic relevance of hypoxia associated protein in PCNSL.16 
Sung et al have recently published their study combin-
ing genomic profiling with gene expression profiling 
and identified novel tumor suppressor genes and path-
ways specific to PCNSL (JAK-STAT, NF-kB pathway, 
Notch signaling pathway) which might serve as poten-
tial therapeutic targets of PCNSL.17
pharmacokinetics
The blood brain barrier (BBB) is the limiting factor 
in delivering biologically active agents to the cen-
tral nervous system (CNS). Certain physical proper-
ties like low molecular weight, lipophilicity and lack 
of   ionization are important to reach the CNS. The 
concept of the blood-brain barrier (BBB) was first 
introduced by Paul Ehrlich more than 100 years ago. 
ABBB is present in 99% of the brain   capillaries. There 
are multiple variables which determine the capability 
of drugs to cross the BBB, such as size, hydrophilia 
and ionization.
There are three major subgroups of drugs which 
differ according to their ability to cross the BBB and 
adequately treat PCNSL. First, there is a group of 
drugs with a very low ability to cross the BBB that can 
be administered at remarkably higher doses to obtain 
therapeutic  concentrations  in  the  tumor  tissue  and 
lymphoma-surrounding neural tissue. This is the case 
with  methotrexate  (MTX)  and    cytarabine.  Second, 
there is a group of drugs with a very low capability 
to cross the BBB and which cannot be administered 
at high doses because of dose-limiting toxicity. This 
is the case with anthracyclines, vinca alkaloids and 
some alkylating agents, which represent the mainstay 
of  treatment  of  systemic  Non-Hodgkin  lymphoma 
(NHL)  but  exhibit  negligible  activity  in  PCNSL. 
Third, there are some chemotherapeutic agents able 
to cross the BBB and reach therapeutic concentra-
tions in the tumor bed. This is the case with thiotepa, 
ifosfamide,  temozolomide  and  nitrosoureas  which 
are frequently  included in  chemotherapy combina-
tions for PCNSL.
The efficacy of MTX depends on the duration of 
infusion and drug concentration. The optimal admin-
istration schedule is still not clear. While standard 
dose MTX does not cross the BBB, doses at 1–3 g/m2 
result in tumoricidal levels in the brain parenchyma 
and doses .3 g/m2 yield tumoricidal levels in the 
CSF. A significantly higher response rate and CSF 
levels have been obtained administering HD-MTX in 
a 3 hour infusion.18 Methotrexate area under the curve 
AUCHD-MTX has been found to be the most most inde-
pendent predictor of clinical outcome in the analy-
sis done by Joerger et al on the patients enrolled in 
IELSG 20 trial.19 This was also previously reported 
by   Ferreri et al 2004.20 Hence, personalized dosing of 
MTX should be used based on patients age, gender and 
creatinine clearance to improve the   outcome.   Various 
drug  delivery  mechanisms  have  been  proposed  to 
overcome  the  BBB.  Intra-arterial  delivery  has  the 
advantage of increased concentration of the drug in 
the CNS with less systemic exposure.   Intrathecal or 
intraventricular delivery produces the most consistent 
CSF levels.
Treatment
Radiotherapy
For many years whole brain radiation therapy (WBRT) 
was the standard treatment for PCNSL patients result-
ing in a median survival of 10–18 months and a 5 year 
overall survival of 10 to 20% with very high relapse 
rates.21 Partial brain irradiation was associated with 
reduced  survival  rates  and  high  recurrence  rates.22 
With  the  addition  of  multidrug  regimens  the  role 
of WBRT seems to be decreasing. Using high dose 
WBRT with 40 Gy followed by boost to the tumor 
bed of 20 Gy showed no increase in overall survival 
as  reported  by  the  Radiation  Therapy  Oncology 
Group RTOG 83–15 trial.23 WBRT alone as a treat-
ment remains an option for elderly patients with mul-
tiple comorbidities or patients with poor performance 
status who cannot tolerate chemotherapy. To optimize 
the treatment outcome of patients with PCNSL stud-
ies were done using combined modality therapy.
chemoradiation Therapy
HD-MTX based treatment showed good response 
in patients with systemic lymphoma who had CNS 
relapse. This led to the use of this drug in PCNSL 
patients. Since the incidence of this tumor is very Prodduturi and Bierman
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low it was difficult to conduct adequately powered 
  randomized phase III clinical trials.24 Studies have 
shown that combined modality therapy (CMT) has 
produced response rates up to 80–90% and median 
overall survival up to 5 years (Table1)25–35 but, this 
came  with  a  major  limitation  of  neurocognitive 
toxicity especially in patients older than 60 years 
of age. There is still a debate as to whether WBRT 
in combination with chemotherapy improves any 
survival.
A randomized study comparing CHOP (cyclophos-
phamide, doxorubicin, vincristine and prednisone) to 
CHOP plus radiotherapy conducted by the   Medical 
Research  Council  was  stopped  because  of  poor 
accrual and showed only minimal effectiveness.36 It 
could be because of the poor penetration of CHOP 
through the BBB achieving sub-therapeutic levels in 
the CSF.
Deangelis  et  al  reported  an  improved  survival 
of 41 months for 31 patients treated with combined 
modality  therapy  consisting  of  pre-irradiation  sys-
temic MTX and intra-thecal (IT) MTX with WBRT 
40 Gy plus boost (14.4 Gy) followed by high dose 
Ara-C compared to a control group treated with RT 
alone (median survival 10 months).25 This was not 
a randomized study and it did not reach statistical 
significance for overall survival (OS) because of the 
small number of patients. The exact dosing of RT and 
the role of boost remains undefined.
Shah et al has shown that reducing the dose of 
WBRT after achieving CR with induction chemother-
apy had no impact on outcome, 32 which was contrary 
Table 1. Combined modality therapy in patients with newly diagnosed primary CNS lymphoma.
study number chemotherapy WBRT (boost) Median  
follow up 
(mon)
cR/pR 
(%)
pFs  
(mon)
Os
De Angelis et al25 31 
 
16
MTX 1 g/m2
 + IT  
MTX, Ara-C 
RT alone
40 Gy (14.4 Gy) 45 88/6 41 
10
42.5 
21.7
O’Brien et al26 46 MTX 1 g/m2 45 Gy (5.4 Gy) 36 82/13 65% 2 yr 33 mon  
2 yr 62%
Abrey et al27 52 MNO + IO MTX 45 Gy 60 87/7 NR 60 mon  
5 yr 40%
Bessel et al28 31 
26
CHOD/BvAM 1 
CHOD/BvAM II
45 Gy 
30.6 Gy (if CR)
49 68 
77
29% 3 yr 
70% 3 yr
5 yr 36% 
3 yr 92§
De Angelis et al29 102 MPv (Iv MTX + IT 
MTX)
45 Gy 56 58/36 24 36.9
Poortmans et al30 52 MBvP + IT  
MTX, Ara-C,  
hydrocortisone
40 Gy 27 86/14 NR 2 yr 69% 
3 yr 58%
Gavrilovic et al31 MTX, vCR, PCB +  
IO MTX
45 Gy 115 NR 129 29 mon
Shah et al32 30 Rituximab, MTX,  
PCB, vCR, Ara-C
23.4 Gy (CR) 
45 Gy if no CR
37 78 2 yr 57% 
40
67% 2 yr 
median 37   
or more
Ferreri et al33 79 MTX or MTX +  
Ara-C
45 Gy 30 46 21% 3 yr 
38% 3 yr
32 
46
Thiel et al34 551 MTX-. MTX +  
IFOS
45 Gy 
No wBRT
50.7 NR 18.3 
11.9
32.4 
37.1
Motomura K et al35 21 Dex + etoposide +  
ifos + carboplatin
40–45 Gy 60 95  
(ORR)
37.4 47.8
note: §3 year 92 vs. 60 in patients less than 60 year old who received 45 Gy vs. 30.6 Gy respectively.
Abbreviations: yr, year; PCB, procarbazine; vCR, vincristine; MTX, methotrexate; Ara-C, cytarabine; CTX, cyclophosphamide; ADR, doxorubicin; Dex, 
dexamethasone; Ifos, ifosfamide; CT, chemotherapy; IT, intrathecal; wBRT, whole-brain radiotherapy; PFS, progression free survival; OS, overall survival; 
IDA,  idarubicin;  IFO,  ifosfamide;  MBvP,  methotrexate,  teniposide,  carmustine,  methylprednisolone;  CHOD/BvAM,  cyclophosphamide,  doxorubicin, 
vincristine, dexamethasone, carmustine, vincristine, cytarabine, methotrexate; CHOP/HDAC, cyclophosphamide, doxorubicin, vincristine and prednisone/
high dose cytarabine; MACOP-B, cyclophosphamide, doxorubicin, methotrexate, vincristine, prednisolone; MNO, methotrexate, procarbazine, vincristine; 
ORR, overall response rate; CR, complete response; PR, partial response.Treatment of primary central nervous system lymphoma
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to data presented by Bessell et al who demonstrated 
that reduced dose of WBRT compromised survival in 
younger patients.28
Ferreri et al has shown that WBRT dose reduc-
tion to 30 Gy in patients with CR after chemotherapy 
was associated with similar outcomes compared to 
those receiving higher radiation doses with reduced 
neurotoxicity.37
A randomized phase 2 study IELSG 20, included 
79 patients assigned to either MTX 3.5 g/m2 alone 
or combined with Ara-C followed by WBRT in both 
arms.33 Patients assigned to the Ara-C arm had an 
improved response (CR 46% vs. 18%) and survival 
rates (3 year OS: 46% vs. 32%) compared with HD-
MTX alone. Most experts in the field think that MTX-
Ara-C combination is the current standard approach 
for newly diagnosed PCNSL patients as it is supported 
by the highest level of evidence.
The combination of high doses of methotrexate 
(MTX) and cytarabine (Ara-C) is the standard che-
motherapy for patients with primary CNS lymphoma 
(PCNSL). Ferreri et al conducted a pilot study to assess 
the efficacy of adding an alkylating agent (thiotepa) 
to the regimen of MTX + Ara-C (MAT). To mini-
mize toxicity the dose of Ara-C was halved. 2-year 
OS of 24% ± 9% was noted. MAT and MTX-Ara-C 
combinations  showed  similar  tolerability,  whereas 
Ara-C dose reduction was associated with a remark-
ably lower efficacy, masking any potential benefit of 
thiotepa.38 Thus the authors have concluded that treat-
ment with full dose of Ara-C 2 g/m2 is important in 
patients with PCNSL.
A recently published randomized trial G-PCNSL-
SG-1 has shown that there was no difference in over-
all survival when radiotherapy was omitted although 
progression free survival (PFS) was longer in patients 
who received WBRT (18.3 months vs. 11.9 months).34 
This study had major protocol violations and flaws 
however.
The dose of WBRT in patients with CR after radio-
therapy remains undefined. It needs to be addressed 
in prospective trials. Combined modality treatment 
prolongs survival compared with WBRT alone and 
remains the mainstay of treatment. Comparing treat-
ments can be difficult because of usage of different 
chemo regimens, different radiation doses and salvage 
therapies. To avoid the neurotoxicity, clinical trials 
have focused on intensifying chemotherapy by using 
poly-chemotherapy or giving high dose chemother-
apy followed by autologous stem cell   transplantation. 
(HDC/ASCT).
chemotherapy Alone
To  avoid  the  late  neurologic  complications   arising 
from  radiation  therapy  studies  have  focused  on 
using chemotherapy alone in patients with PCNSL 
(Table 2).39–51
Single  agent  methotrexate  has  been  tested  in 
phase  II  studies.  The  study  reported  by  Batchelor 
et al using HD-MTX at 8 gm/m2 showed an objective 
response rate of 74% with progression free survival 
of 12.8 months and median overall survival (OS) was 
not reached at 22.8 months.45 An update on this study 
showed a median survival of 55 months.52 Elderly 
patients also tolerated the regimen well although most 
of them required dose reductions due to impaired cre-
atinine clearance. High dose methotrexate alone as 
initial treatment is still controversial.
Guha-Thakurta  et  al  reported  their  results  on 
induction  chemotherapy  MTX  8  g/m2  followed 
by  maintenance  therapy  at  3.5  g/m2  at  3  month 
  intervals.41  Median  PFS  was  17  months  and  the 
median OS was 30 months with an objective response 
rate (ORR) of 100% with a 65% CR rate. The regi-
men was well tolerated with preservation of cog-
nitive and memory skills. The baseline Karnofsky 
performance score (KPS) (median 40) was very low 
demonstrating a significant benefit of this approach 
in severly ill patients. Two subsequent studies failed 
to  produce  similar  results  however.42,45  Although 
MTX as a single agent has better side effect profile, 
to improve the outcome it may be necessary to add 
other agents.
A phase II study conducted by the EORTC group 
in elderly patients with PCNSL reported a median 
survival of 14.3 months and 1 year PFS of 40% when 
using a regimen that consisted of high-dose metho-
trexate,  lomustine,  procarbazine,  methylpredniso-
lone, IT chemotherapy with MTX and cytarabine.43 
Most patients preserved their cognitive function and 
KPS, with myelosuppression being the most frequent 
side effect. In this patient population, chemotherapy 
alone produced comparable results with WBRT and 
without any significant cognitive toxicity.
Pels  et  al  conducted  a  pilot  study  using  high 
dose  MTX  and  cytarabine  based  therapy    including Prodduturi and Bierman
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  dexamethasone,  vinca  alkaloids,  ifosfamide,    cyclo-
phosphamide  with  intraventricular  MTX,  pred-
nisolone  and Ara-C.44  The  median  overall  survival 
was 50 months and median time to treatment failure 
was  21  months.  For  patients  older  than  60  years 
median survival was 34 months. Permanent cognitive 
dysfunction occurred in only 3% of patients. Response 
rates  and  duration  were  comparable  to  the  results 
reported after combined chemo-radiotherapy.
A phase II study by Chamberlain et al reported their 
data on chemotherapy alone in patients with newly 
diagnosed  PCNSL.48  Their  regimen  included  HD-
MTX and rituximab with deferred WBRT. Median OS 
was 29 months with median PFS of 21 months. About 
40% of patients were greater than 70 years old.
Temozolomide as upfront therapy tested in elderly 
patients  is  associated  with  a  median  survival  of 
21 months with 47% CR rate.49 In this study 5 of 
17 patients (29.4%) had prolonged responses for at 
least 12 months and overall survival of more than 
24 months. Of these five patients three had a meth-
ylated  O6-methylguanine-DNA  methyltransferase 
(MGMT) promoter. Temozolomide alone remains an 
option in frail elderly patients who otherwise cannot 
receive HD-MTX based treatment.
A phase 2 study done by the CALGB (Cancer and 
Leukemia Group B) reported a 3 year PFS of 50% and 
OS of 67% using a combination of HD-MTX, temo-
zolomide, and rituximab followed by consolidation 
with HD-Ara-C and HD etoposide without WBRT.53
Intra-Arterial chemotherapy  
with Blood Brain Barrier  
Disruption (BBBD)
The major challenge in PCNSL is to deliver thera-
peutic  concentrations  of  drugs  to  the  CNS.  The 
safety  and  efficacy  of  intra-arterial  chemotherapy 
in  conjunction  with  blood-brain  barrier  disruption 
has been documented in few studies.39,54 The open-
ing of tight junctions with osmotic disruption with 
mannitol allows increased levels of drugs up to 50 to 
100 fold. Angelov et al reported their data on intra-
arterial chemotherapy with BBB disruption suggest-
ing a CR rate of 58% with 5 year progression free 
survival of 31%.47 Tyson et al reported a retrospec-
tive study on patients with relapsed PCNSL treated 
with second line intra-arterial carboplatin-based che-
motherapy plus BBBD.55 The protocol was repeated 
every 4 weeks for up to 1 year. Overall response 
rate was 35% with a median survival of 6.8 months. 
Table 2. Chemotherapy alone in patients with newly diagnosed PCNSL.
study number Treatment cR (%) pFs 
(months)
Os 
(months)
Neuwelt et al39 17 MTX (IA) 2.5 g + PCB + CTX 81 NR 44
Sandor et al40 14 MTX + TTP + vCR + IT CT 79 16 .40
Guha Thakurta et al41 31 MTX 8 g/m2 100 NR 63% 2 year
Herrlinger et al42 37 MTX 8 g/m2 30 10 25
Hoang-Xuan et al43 50 MTX + lomustine + procarbazine +  
methylpred + IT MTX/Ara-C
42 6.8 14.3
Pels et al44 61 MTX, Ara-C, CTX, IFOS, vCR,  
DXM + IT Ara-C, MTX prednisolone
61 21¥  
50
Batchelor et al45 25 MTX 8 g/m2 52 12.8 55.4
Omuro et al46 23 MTX + temozolomide 55 8.0 35
Angelov et al47 149 BBBD + IA MTX 2.5 g/m2  
+/- etoposide, CTX, PCB
58 21.6 37.2
Chamberlain et al48 40 HD-MTX + rituximab (8 g/m2;  
375 mg/m2)
60 21 33.5
Kurzwelly et al49 17 Temozolomide 47 5.0 21
Gerard LM et al50 23 HD-MTX + vCR + PCB 60 4.6 41.4
Fritsch K et al51 28 Rituximab + MTX + PCB + lomustine 64 31% 3 year 31% 3 year
note: ¥TTF, time to treatment failure.
Abbreviations: NR, not reported; CTX, cyclophosphamide; PCB, procarbazine; TTP, thiotepa; vCR, vincristine; IT, intrathecal; CT, chemotherapy; MTX, 
methotrexate; BBBD, blood brain barrier disruption; IA, intra-arterial; DXM, dexamethasone; IFOS, ifosfamide; methylpred, methylprednisolone; CR, 
complete response; PFS, progression free survival; OS, overall survival; TTF, time to treatment failure.Treatment of primary central nervous system lymphoma
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Six patients were alive at 42.8, 50.4, 50.9, 54.7 and 
91 months from first carboplatin/BBBD   treatment. 
The potential advantages of this approach are achiev-
ing prolonged durable remissions without any neu-
rocognitive  sequelae  associated  with  WBRT.  The 
disadvantages include requiring g  eneral anesthesia 
with an increase incidence of stroke, thrombosis and 
seizures and this can be only done in major centers 
with expertise. IA chemotherapy with BBB disrup-
tion is being tested in multicenter trials.
Intrathecal chemotherapy (IT)
Leptomeningeal involvement in PCNSL occurs in 
about 37% of patients.25 The concentration of MTX 
between plasma and CSF is approximately 100:1 
when  given  intravenously.56  The  serum  half-life 
of MTX after a 24-hour infusion is 2 to 4 hours 
  depending  on  the  dose,  while    intraventricular 
administration  produces  a  CSF  half-life  of  up  to 
48 hours.57,58,59 The role of IT chemotherapy is not 
clear. CSF acts as a sanctuary for PCNSL tumor 
cells leading to increased risk of relapses. Large ret-
rospective studies have not shown any benefit with 
the addition of IT chemotherapy in patients treated 
with high dose MTX.60,61 Pels et al reported their data 
on 65 patients with PCNSL who were treated with 
MTX-Ara-C  based  therapy  combined  with  intra-
ventricular MTX, Ara-C and steroids. Median PFS 
was 21 months, with 57% of young patients being 
alive at a median   follow up of 100 months.44 In a 
second trial conducted by the same author patients 
received  the  same  c  hemotherapy  without  intra-
ventricular drug delivery.62 Although the response 
rates were similar, more than half of the patients 
relapsed within the first year   leading to the prema-
ture termination of the trial. A phase 1 study con-
ducted by Rubenstein et al has shown some activity 
of intraventricular rituximab.63 Currently g  uidelines 
do  not  recommend  intrathecal/  intraventricular 
  chemotherapy to be included in the treatment regi-
men,  although  many  physicians  r  ecommend  in 
patients with   positive CSF cytology.
High Dose chemotherapy with 
Autologous stem cell Transplantation 
(HDc/AscT)
Current knowledge in PCNSL management results 
from a limited number of single-arm phase II trials, 
meta-analyses and large retrospective series. HDC/
ASCT has been tested as salvage treatment in patients 
with recurrent or refractory PCNSL, and as consoli-
dation after primary chemotherapy, replacing or pre-
ceding whole-brain irradiation (Tables 3 and 4).64–72 
The rationale for the use of HDC/ASCT is to admin-
ister intensive doses of chemotherapy to overcome 
drug resistance and to achieve therapeutic concentra-
tions in the lymphoma tissue and other sanctuaries, 
like cerebrospinal fluid (CSF), meninges and eyes. 
The results have been variable when used as first line 
therapy for newly diagnosed patients.73 The results are 
not consistent among the trials because of usage of 
different induction regimens, consolidation treatment 
and the use of WBRT. Among induction regimens 
MTX based polychemotherapy was more effective. 
Among  consolidation  regimens  BEAM  (carmus-
tine, etoposide, cytarabine, and melphalan) regimen 
was ineffective although it is a standard regimen for 
other  aggressive  lymphomas.  Thiotepa  based  regi-
mens were more effective. The discrepancies could 
be related to different CNS penetration of the drugs. 
Busulfan, carmustine and thiotepa exhibit good CNS 
penetration with CSF levels exceeding 50%–80% of 
serum levels, while drugs in the BEAM regimen have 
poor CNS penetration rates of 5%–22%.74
Abrey et al treated 28 patients with an induction 
regimen consisting of MTX 3.5 g/m2 and Ara-C 3 g/m2 
followed  by  conditioning  which  included  BEAM 
therapy.64 Only 57% achieved CR. Median time to 
progression after transplant was 9.3 months. Since 
the response rates were poor with this therapy subse-
quent trials have focused on intensifying therapy and 
using different conditioning regimen.
Cheng  et  al  also  reported  their  data  using  high 
dose  MTX  based  regimen  for  induction  followed 
by  thiotepa,  busulfan,  and  cyclophosphamide.63  In 
patients  with  poor  prognostic  factors  six  of  seven 
achieved CR.
Illerhaus et al reported their data using a regimen 
that included 3 cycles of HD-MTX 8 g/m2, Ara-C, 
and  thiotepa.66  Patients  received  carmustine  and 
thiotepa before transplant. WBRT of 45 Gy was given 
to patients who had CR and 50 Gy to those who had a 
partial response. 15/30 patients had a CR with induc-
tion therapy and an additional six achieved CR after 
WBRT. The 5 year survival was 69% in this study. 
The same group reported their data in a small phase Prodduturi and Bierman
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2  study  suggesting  that  HDC/ASCT  could  replace 
WBRT as a consolidation treatment by achieving a 
3 year survival of 77% (2008) with no   neurotoxicity.68 
Comparison is difficult since the two studies were 
done in different settings.
Soussain et al reported the results of a prospec-
tive multicenter trial of intensive chemotherapy fol-
lowed by autologous hematopoietic stem-cell rescue 
in patients with PCNSL who failed HD-MTX-based 
treatment.70,71  The  treatment  consisted  of  2  cycles 
of  HD  cytarabine  and  etoposide  (CYVE)  and  the 
conditioning  regimen  was  thiotepa,  busulfan  and 
cyclophosphamide. About 15 out of 20 patients with 
chemo-sensitive  disease  and  12  non-responders 
underwent HDC/ASCT.
The median PFS was 11.6 months and the median 
OS was 18.3 months in the overall population and 
41.1 months and 58.6 months among patients who 
completed intensive chemotherapy followed by autol-
ogous hematopoietic stem-cell rescue,   respectively. 
Intensive  chemotherapy  followed  by  autologous 
hematopoietic  stem-cell  rescue  remains  an  effec-
tive  treatment  option  in  patients  with  recurrent  or 
refractory PCNSL but remains an option as part of 
first line therapy. The two ongoing randomized trials 
(NCT01011920;  NCT00863460)  will  establish  the 
most effective way to consolidate therapy either with 
WBRT or HDC/ASCT.
salvage Therapy
About  30%–60%  of  patients  with  PCNSL  eventu-
ally  relapse.  Treatment  options  for  these  patients 
are limited and the prognosis is poor. The reported 
median survival of these patients is only 2 months if 
Table 3. High dose chemotherapy followed by autologous stem cell transplantation in patients with newly diagnosed 
PCNSL.
Author/study number  
of patients
Treatment 
induction
conditioning 
regimen
Median  
follow up
ORR (%) Os
Cheng et al63 7 HD-MTX →  
Ara-C
BU/TT/CY 
No wBRT
28 84 50% 3 year
Abrey et al64 28 HD-MTX →  
Ara-C
BeAM 
No wBRT
28 18 55% 2 year
Brevet et al65 6 MBvP + IFO +  
Ara-C
BeAM 
wBRT
41.5 100 40% 2 year
Illerhaus et al66 30 BCNU/TT +  
wBRT
63 65 69% 5 year
Montemurro et al67 23 HD-MTX BU/TT wBRT 15 83 48% 2 year
Illerhaus et al68 13 HD-MTX →  
Ara-C + TT
 
BCNU/TT +/- 
wBRTβ
23 NR 77% 3 year
Alimohamed et al69 21 TBC No wBRT 60 NR 52% 5 year
note: βwBRT given to patients who did not achieve a complete remission.
Abbreviations: Ara-C, cytarabine; ASCT, autologous stem cell transplantation; BCNU, carmustine; BeAM (regimen), carmustine, etoposide, cytarabine, 
and melphalan; Bu, busulfan; Cy, cyclophosphamide; IFO, ifosfamide; MBvP 77% 3 year, methotrexate, carmustine, etoposide, and methylprednisolone; 
TT, thiotepa; wBRT, whole-brain irradiation; ORR, objective response rate; thiotepa, busulfan, cyclophosphamide (TBC); OS, overall survival; HD-MTX, 
high dose methotrexate.
Table 4. High dose chemotherapy followed by autologous stem cell transplantation in patients with relapsed and 
refractory PCNSL.
study number Induction conditioning  
regimen
Median follow  
up (months)
cR (%) Os
Soussain et al70 22 Ara-C + vP16 Bu/TT/Cy 
no wBRT
41 80 64% 3 year
Soussain et al71 43 Ara-C + vP16 Bu/TT/Cy 
no wBRT
36 72 45% 2 year
Abbreviations: Ara-C, cytarabine; ASCT, autologous stem cell transplantation; Bu, busulfan; Cy, cyclophosphamide; vP16, etoposide; TT, thiotepa; 
wBRT, whole-brain irradiation; OS, overall survival; CR, complete response.Treatment of primary central nervous system lymphoma
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left untreated and with treatment the median survival 
goes up to 14 months (Table 5).54,62,75–86
When chemotherapy is used as first line treatment 
WBRT can be used as salvage treatment. Hottinger 
et al conducted a retrospective study to evaluate the 
safety and efficacy of salvage WBRT.79 Median sur-
vival was 16 months with 1 year survival of 54%.
Similarly  Nguyen  et  al  reported  their  data  on 
WBRT as salvage therapy for PCNSL. The median 
dose of WBRT was 36 Gy.77 37% achieved a CR rate. 
Median survival was 10.9 months and median PFS 
was 9.7 months. Khimani et al have reported an over-
all survival of 11.7 months with a CR of 50% with 
salvage WBRT in patients with primary or secondary 
CNSL.83 The median survival after salvage WBRT is 
comparable to the treatment with WBRT given as a 
first line treatment.
HD-MTX  remains  an  option  for  patients  with 
relapsed  PCNSL  who  initially  responded  to  HD-
MTX. Plotkin et al performed a multicenter, retro-
spective study of high-dose methotrexate in patients 
with relapsed PCNSL.75 Overall response rate was 
91% to first salvage and 100% to second salvage. 
The  reported  median  survival  was  62  months. 
The  most  common  toxicity  observed  was  mainly 
hematologic.
Reni et al reported their phase II trial assessing 
temozolomide  in  recurrent  PCNSL  patients  previ-
ously  treated  with  HD-MTX  chemotherapy  and/or 
radiotherapy.80 A response rate of 31% was observed 
with a median PFS of 2.8 months and median overall 
survival of 3.9 months.
Makino  et  al  evaluated  the  methylation  status 
of  MGMT  gene  promoter  region  in  patients  with 
or  relapsed  refractory  PCNSL.  The  primary  treat-
ment  was  HD-MTX  (3.5  g/m2)  with  or  without 
  irradiation. Patients were treated with temozolomide 
150–200 mg/m2, for 5 days every 28 days.
There  were  five  complete  remissions  with  five 
partial responses (PRs). Median overall survival was 
6.7 months. MGMT promoter methylation was found 
in 4 (36.4%). Median overall survival was not sig-
nificantly different between patients with methylated 
MGMT (11.1 months) and non-methylated MGMT 
(6.7 months).85
Enting et al reported their retrospective data using 
a  combination  of Temozolomide  plus  Rituximab.76 
Rituximab (750 mg/m2) was given on days 1, 8, 15 
and 22, and Temozolomide (100–200 mg/m2) on days 
1–7 and 15–21. Median PFS for responding patients 
was 7.7 months with a median survival of 14 months. 
The toxicity was minimal. This combination might be 
an option in elderly patients.
Topotecan, is a topoisomerase I inhibitor which 
can cross the BBB and reach therapeutic concentra-
tions in the CSF. Fischer et al reported the results of a 
prospective study on Topotecan in relapsed or refrac-
tory PCNSL.78 The overall response rate was 33%, 
with 5 CRs and 4 PRs. The median PFS was 2 months 
(9.1 months in responders). The overall survival was 
Table 5. Salvage treatment in patients with relapsed/refractory primary CNS lymphoma.
study number Treatment cR% + pR% pFs (mon) Os (mon)
Tyson et al54 37 IA Carboplatin + vP16 + CTX 24 + 11 3.0 6.8
Arellano-Rodrigo et al74 16 vP16 + ifosfamide + Ara-C 37 + 0 5.0 40$
Plotkin et al75 22 Methotrexate 73 + 19 NR 62
enting et al76 15 Temozolomide + rituximab 40 + 13 2.2 10.5
Nguyen et al77 27 wBRT 37 + 37 9.7 10.9
Fischer et al78 27 Topotecan 19 + 14 2.0 8.4
Hottinger et al79 48 wBRT 58 + 21 10 16
Reni et al80 36 Temozolomide 25 + 6.0 2.8 3.9
Iwamoto et al81 6.0 Y 90-ibritumomab tiuxetan 3.3 + 0.0 NR 1.6
Rubenstein et al62 10 Intraventricular rituximab 0 + 60 NR 5.2
voloschin et al82 15 Topotecan 6.0 + 15 2.0 3.2
Khimani et al83  36 wBRT 50 + 17 NR 11.7
Raizer JJ et al84 11 Pemetrexed 55 (ORR) 5.7 10.1
Makino K et al85 17 Temozolomide 29 + 0 NR 6.7 to 11.1
note: $1 year survival.
Abbreviations: NR, not reported; Mon, months; wBRT, whole brain radiotherapy; CR, complete remission; PR, partial remission; PFS, progression free 
survival; OS, overall survival; vP16, etoposide; CTX, cyclophosphamide; Ara-C, cytarabine; IA, intra-arterial.Prodduturi and Bierman
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8.4 months with 1-year survival of 39%. Additional 
radiation therapy after topotecan treatment resulted in 
a longer survival time in the resistant patient group. 
Grade 3/4 leucopenia or thrombocytopenia occurred 
in 26% and 11% of the patients, respectively.
Similarly,  Voloschin  et  al  reported  a  Phase  II 
study that included 15 refractory or relapsed PCNSL 
patients with a median age of 56 years.82 The treat-
ment consisted of intravenous topotecan for 5 con-
secutive days every 3 weeks . Three patients achieved 
CR with a median PFS of 2 months.
Eleven of the 15 patients had grade 3/4 neutro-
penia and 3 patients had grade 3 thrombocytopenia. 
  Topotecan is active in relapsed and refractory PCNSL 
but  hematologic  toxicity  remains  a  major  concern 
especially in elderly patients.
Rituximab  is  a  chimeric  monoclonal  antibody 
against the CD-20 antigen with a molecular weight 
of 145 kDa. Rituximab achieves a CSF concentra-
tion of only 0.1% of serum levels after intravenous 
infusion. A Phase 1study conducted by Rubenstein 
et al consisted of intrathecal rituximab thru Ommaya 
reservoir.62  Median  survival  reported  was  about 
5.2 months. Rituximab is being tested in combination 
with other chemotherapy.  90Y-ibritumomab tiuxetan 
is a murine anti-CD20 linked to the Yttrium-90 by the 
chelator tiuxetan. Iwamoto et al reported their data on 
6 patients using  90Y-ibritumomab.81 Median overall 
survival reported was only 1.6 months.
Tyson et al reported a retrospective study on patients 
with  relapsed  PCNSL  treated  with    second  line  IA 
  carboplatin-based chemotherapy plus BBBD.54   Overall 
response  rate  was  35%  with  a  median  survival  of 
6.8 months. However, a CTC grade 3/4   hematological 
adverse  event  was  seen  in  41%  of  the  patients. 
  Ototoxicity was reported in 3% of the patients prob-
ably due to carboplatin.
Poly-chemotherapy  was  also  tested  in  patients 
with relapsed or refractory PCNSL.
Arellano-Rodrigo  et  al  reported  a  retrospective 
study  of  16  patients  with  refractory  and  recurrent 
PCNSL.74 The first line treatment used in all these 
patients  was  cyclophosphamide,  doxorubicin,  vin-
cristine,  dexamethasone/carmustine,  vincristine, 
cytarabine  and  methotrexate  (CHOD/BVAM)  and 
radiotherapy,  followed  by  VP16,  ifosfamide  and 
Ara-C (VIA) chemotherapy as a salvage treatment. 
Six patients (37%) achieved CR with a median PFS 
of 5 months and 1-year overall survival of 41%. The 
major toxicity was hematologic. VIA chemotherapy 
remains an option in patients with refractory/recur-
rent PCNSL.
A  case  report  submitted  by  Renfrow  et  al  has 
shown that there might be a role of Bendamustine in 
the treatment of relapsed PCNSL patients. The phar-
macokinetics and efficacy needs to be further tested 
in larger trials.86
Raizer  et  al  have  recently  published  their  data 
on  relapsed  and  refractory  patients  with  PCNSL. 
Pemetrexed at 900 mg/m2 was given to 11 patients. 
Median PFS of 5.7 months and an OS of 10.1 months 
was  observed.  Mainly  hematologic  and  infectious 
toxicity was noted. The optimal dosing and efficacy 
needs further investigation.84
conclusion
In the past few years considerable progress has been 
made in the treatment of PCNSL. It is difficult to con-
duct randomized prospective trials because of the low 
incidence of this disease. The ongoing randomized 
trials might provide some insight into the new treat-
ment combinations, the most effective consolidation 
treatment with improved efficacy and less toxicity. To 
achieve  this,  international  multicenter  trials  should 
be conducted. Every patient should be enrolled in a 
clinical trial if eligible. There are many unanswered 
questions at this time as to the best initial treatment 
in younger and older patients, in whom WBRT could 
be omitted without compromising survival, the role 
of intra-thecal chemotherapy and the setting of HDC/
ASCT.  Recently  published  data  suggests  a  role  of 
certain  pathways  like  JAK-STAT,  NF-kB,  NOTCH 
signaling  which  could  serve  as  potential  targets  of 
therapy. HD-MTX based combination chemotherapy 
with or without WBRT remains the primary treatment 
of choice in patients with PCNSL at the present time.
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